Evidence map›Paper›PMID 38398185›Full record

ReviewCancers2024

Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges.

Julianne M Szczepanski, Mark A Rudolf, Jiaqi Shi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Julianne M SzczepanskiDepartment of Pathology and Clinical Labs, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-5687-9857
Mark A RudolfDepartment of Pathology and Clinical Labs, University of Michigan, Ann Arbor, MI 48109, USA.
Jiaqi ShiDepartment of Pathology and Clinical Labs, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-4893-1587

Funding

Defining epigenetic signaling to reshape pancreatic tumor microenvironmentR37CA262209 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiaqi Shi · 2022 to 2026
$2.3M
NCI NIH HHS R37 CA262209NCI NIH HHS R37CA262209
6 · The paper itself

Abstract

Advances in our understanding of pancreatic ductal adenocarcinoma (PDAC) and its tumor microenvironment (TME) have the potential to transform treatment for the hundreds of thousands of patients who are diagnosed each year. Whereas the clinical assessment of cancer cell genetics has grown increasingly sophisticated and personalized, current protocols to evaluate the TME have lagged, despite evidence that the TME can be heterogeneous within and between patients. Here, we outline current protocols for PDAC diagnosis and management, review novel biomarkers, and highlight potential opportunities and challenges when evaluating the PDAC TME as we prepare to translate emerging TME-directed therapies to the clinic.

Indexed as

biomarkermanagementpancreatic ductal adenocarcinomapathologytumor microenvironment

Identifiers

PMID38398185
PMCPMC10887250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.